Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles

After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.

Scientist

Underpinned by a strong background in the CNS space and experience with the orexin system, Medicxi, the European life sciences venture capitalist, is investing up to €40m in two asset-centric companies with assets spun out of Sosei Group's Heptares Therapeutics Ltd.. Both companies will focus on developing novel therapies based on positive modulators of the G protein-coupled receptors Orexin OX1 and OX2 for neurological diseases, including dual OX1/OX2 agonists. This is a group of molecules that has been on Medicxi’s wish list for some time.

More from Neurological

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

More from Therapy Areas

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By 

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.